As the cost of sequencing is declining, the adoption of NGS services has increased rapidly. NGS has enabled the discovery of genetically targeted drugs and blood tests that can detect cancer at early stages. It has also enabled diagnosis for people with rare diseases. The declining cost of sequencing has increased its adoption in clinical applications. Thus, the declining sequencing costs are expected to drive the growth of the NGS services market.

Read More: https://www.meticulousresearch.com/product/next-generation-sequencing-services-market-5041